Endocrinology and ageing

2021 ◽  
pp. 703-718
Author(s):  
Antonia Brooke ◽  
Andrew McGovern

Ageing causes changes in many hormonal areas. This chapter begins with an overview of these changes, and goes on to bone disease in the elderly, changes in growth hormones and IGF-1, differences in gonadal function and adrenal function, and then thyroid and pituitary disease in the ageing patient.

Bone ◽  
1994 ◽  
Vol 15 (6) ◽  
pp. 727-728 ◽  
Author(s):  
J.A. Kanis ◽  
C. Cooper ◽  
R. Francis ◽  
N. Hamdy ◽  
P. Selby ◽  
...  

1984 ◽  
Vol 19 (1) ◽  
pp. 18-22 ◽  
Author(s):  
C. Foresta ◽  
G. Ruzza ◽  
R. Mioni ◽  
G. Guarner ◽  
R. Gribaldo ◽  
...  

Bone ◽  
1994 ◽  
Vol 15 (6) ◽  
pp. 725
Author(s):  
P. Selby
Keyword(s):  

1983 ◽  
Vol 152 (S3) ◽  
pp. 15-17
Author(s):  
Malachy McKenna
Keyword(s):  

Author(s):  
R. L. Prince

Bone disease is a common problem in the elderly, and its clinical manifestation are a major preventable public health problem. The disorders of the skeleton have been classified in a variety of ways, an approach which tends to restrict understanding of the clinical problem in a particular patient. Frequently, several separate disorders coexist, each contributing to impairment of bone form or function, and each requiring a separate intervention. The major categories of disorder are osteoporosis, too little bone within the bone, osteomalacia, impaired mineralization of bone matrix, and infiltration of bone with cancer cells. Each represents a distinct pathological processes that results in abnormal bone structure and function, which may present as bone pain and/or fracture.


1995 ◽  
Vol 24 (suppl 2) ◽  
pp. P9-P9
Author(s):  
A. Toogood ◽  
P. O'Neill ◽  
S. Shalet

2011 ◽  
Vol 119 (09) ◽  
pp. 519-524 ◽  
Author(s):  
S. Polyzos ◽  
A. Anastasilakis ◽  
P. Makras ◽  
E. Terpos

AbstractPaget’s disease of bone (PDB) is the second most common metabolic bone disease. Bisphosphonates (BPs) are currently the drugs of choice for PDB. PDB and osteomalacia are both common in the elderly. The concept of relative vitamin D deficiency in patients with PDB was suggested long ago, but it has not yet elucidated. Both diseases predispose to fractures, but their combined action to fragility has not been studied yet. The older BPs, mainly etidronate, further inhibit bone mineralization. Mineralization defects have also been described in patients with PDB treated with pamidronate. Moreover, hypocalcemia and secondary hyperparathyroidism after treatment with BPs have been described in PDB. Hypocalcemia seems to be more severe after treatment with the more potent, intravenous zoledronic acid, which is currently the treatment of choice for PDB. The counteracting hyperparathyroidism pathophysiologically intends to increase renal reabsorption of calcium and 1.25-dihydroxy vitamin D production and to stimulate osteoclasts in order to prevent long-term hypocalcemia. However, the effect of PTH on osteoclasts is, at least partly, restricted in patients taking BPs. Secondary hyperparathyroidism is a potentially detrimental condition, especially in patients already suffering from another bone disease. Serum calcium and vitamin D deficiency should be restored before BP treatment and calcium and vitamin D administration should be possibly continued for longer after achieving normocalcemia, which may shorten the duration of secondary hyperparathyroidism.Mineralization defects and hypocalcemia with secondary hyperparathyroidism have been described in patients with Paget’s disease of bone treated with bisphosphonates. Secondary hyperparathyroidism may be a potentially detrimental condition for patients with Paget’s disease of bone.


1968 ◽  
Vol 10 (6) ◽  
pp. 334-339 ◽  
Author(s):  
M.F. Green ◽  
M. Friedman

Sign in / Sign up

Export Citation Format

Share Document